It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Circulating tumor cells (CTCs) have gathered attention as a biomarker for carcinomas. However, CTCs in sarcomas have received little attention. In this work, we investigated cell surface proteins and antibody combinations for immunofluorescence detection of sarcoma CTCs. A microfluidic device that combines filtration and immunoaffinity using gangliosides 2 and cell surface vimentin (CSV) antibodies was employed to capture CTCs. For CTC detection, antibodies against cytokeratins 7 and 8 (CK), pan-cytokeratin (panCK), or a combination of panCK and CSV were used. Thirty-nine blood samples were collected from 21 patients of various sarcoma subtypes. In the independent samples study, samples were subjected to one of three antibody combination choices. Significant difference in CTC enumeration was found between CK and panCK + CSV, and between panCK and panCK + CSV. Upon stratification of CK+ samples, those of metastatic disease had a higher CTC number than those of localized disease. In the paired samples study involving cytokeratin-positive sarcoma subtypes, using panCK antibody detected more CTCs than CK. Similarly, for osteosarcoma, using panCK + CSV combination resulted in a higher CTC count than panCK. This study emphasized deliberate selection of cell surface proteins for sarcoma CTC detection and subtype stratification for studying cancers as heterogeneous as sarcomas.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Florida, Interdisciplinary Microsystems Group, Department of Mechanical and Aerospace Engineering, Gainesville, USA (GRID:grid.15276.37) (ISNI:0000 0004 1936 8091)
2 University of Florida, Department of Pediatrics, Division of Hematology-Oncology, Gainesville, USA (GRID:grid.15276.37) (ISNI:0000 0004 1936 8091)
3 University of Florida, Department of Radiation Oncology, Gainesville, USA (GRID:grid.15276.37) (ISNI:0000 0004 1936 8091)
4 University of Florida, Interdisciplinary Microsystems Group, Department of Mechanical and Aerospace Engineering, Gainesville, USA (GRID:grid.15276.37) (ISNI:0000 0004 1936 8091); University of Florida, J. Crayton Pruitt Family Department of Biomedical Engineering, Gainesville, USA (GRID:grid.15276.37) (ISNI:0000 0004 1936 8091)